Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CMLGlobeNewsWire • 10/17/25
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)GlobeNewsWire • 10/16/25
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump DealZacks Investment Research • 10/08/25
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)PRNewsWire • 09/30/25
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the USGlobeNewsWire • 09/29/25
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025GlobeNewsWire • 09/26/25
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapiesGlobeNewsWire • 09/24/25